Sandoz, Amgen reach agreement resolving patent litigation over biosimilars

seekingalpha04-30

Swiss drugmaker Sandoz (OTCQX:SDZNY) on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen (NASDAQ:AMGN) resolving all patent disputes between the two companies relating to the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2431036662?lang=en_US&edition=fundamental","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg","is_english":true,"pubTime":"2024-04-30 15:32","share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","id":"2431036662","market":"hk","top_or_hot":-1,"title":"Sandoz, Amgen reach agreement resolving patent litigation over biosimilars","media":"seekingalpha","content":"<div>\n<p>Swiss drugmaker Sandoz (OTCQX:SDZNY) on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen (NASDAQ:AMGN) resolving all patent disputes between the two companies relating to the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095970-sandoz-amgen-reach-agreement-resolving-patent-litigation\">Source Link</a>\n\n</div>\n","source":"seekingalpha","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sandoz, Amgen reach agreement resolving patent litigation over biosimilars</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSandoz, Amgen reach agreement resolving patent litigation over biosimilars\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-04-30 15:32 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/4095970-sandoz-amgen-reach-agreement-resolving-patent-litigation><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Swiss drugmaker Sandoz (OTCQX:SDZNY) on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen (NASDAQ:AMGN) resolving all patent disputes between the two companies relating to the ...</p>\n\n<a href=\"https://seekingalpha.com/news/4095970-sandoz-amgen-reach-agreement-resolving-patent-litigation\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1023059063.AUD","symbol_name":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","start_time":0,"source_url":"https://seekingalpha.com/news/4095970-sandoz-amgen-reach-agreement-resolving-patent-litigation","article_id":"2431036662","we_media_id":null,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1328507495/image_1328507495.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2431036662","pubTimestamp":1714462368,"sourceInfo":{"source_id":"seekingalpha","name":"Seeking Alpha"},"weMediaInfo":null,"summary":"Swiss drugmaker Sandoz  on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen  resolving all patent disputes between the two companies relating to the Food and Drug Administration-approved Sandoz denosumab biosimilars. The settlement clears the path to bring both denosumab biosimilars, Jubbonti and Wyost, to the U.S. market on May 31, 2025, or earlier under certain circumstances, Sandoz  said in a statement. Sandoz received FDA approval for the first denosumab biosimilars to treat skeletal-related events and osteoporosis on March 5, 2024. Sandoz  further added that the terms of the agreement will not impact the company's previously disclosed 2024 guidance.","collect":0,"end_time":0,"defaultTopTitle":"seekingalpha.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1023059063.AUD":"BGF WORLD HEALTHSCIENCE \"A2\" (AUDHDG) ACC","LU2242646821.SGD":"Fidelity Global Dividend Plus A-MINCOME(G)-SGD","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4534":"瑞士信贷持仓","BK4139":"生物科技","BK4533":"AQR资本管理(全球第二大对冲基金)","BK4007":"制药","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","BK4566":"资本集团","LU2242652126.USD":"FIDELITY FUNDS GLOBAL DIVIDENDS PLUS \"A\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4588":"碎股","AMGN":"安进","LU0868494617.USD":"UBS (LUX) EQUITY SICAV - US TOTAL YIELD SUSTAINABLE \"P\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","BK4581":"高盛持仓","SDZNY":"Sandoz Group AG","SG9999001440.SGD":"United Global Dividend Equity Fund A SGD Dist","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC"},"translate_title":"山德士与安进达成协议解决生物仿制药专利诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SDZNY":1,"AMGN":1},"content_text":"Swiss drugmaker Sandoz (OTCQX:SDZNY) on Tuesday said that it has reached an agreement with U.S. drugmaker Amgen (NASDAQ:AMGN) resolving all patent disputes between the two companies relating to the Food and Drug Administration-approved Sandoz denosumab biosimilars. The settlement clears the path to bring both denosumab biosimilars, Jubbonti and Wyost, to the U.S. market on May 31, 2025, or earlier under certain circumstances, Sandoz (OTCQX:SDZNY) said in a statement. Sandoz received FDA approval for the first denosumab biosimilars to treat skeletal-related events and osteoporosis on March 5, 2024. Sandoz (OTCQX:SDZNY) further added that the terms of the agreement will not impact the company's previously disclosed 2024 guidance.","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2431036662"}